Khan Najat - Insider Non-Derivative Transactions at RECURSION PHARMACEUTICALS, INC. (RXRX) - (SEC)

Updated on January 3, 2026.

According to recent SEC insider information filed on Dec 22, 2025, Khan Najat's relationship to RECURSION PHARMACEUTICALS, INC. (RXRX) is Director,Officer (Chief R&D Commercial Officer), and currently has 611,135 shares of Class A Common Stock.

The chart below shows the number of shares owned, and the table shows the recent insider transactions.

You can see similar information for other RXRX insiders.

Related Topics: SEC Topic List.

Data Source: SEC.

Khan Najat - Insider Non-Derivative Transactions of RXRX Class A Common Stock

Khan Najat - Insider Non-Derivative Transactions at RXRX

Items per page:

0 of 0

Date	Transaction	No. of Shares	Price Per Share	Shares Owned After Transactions
Dec 23, 2025	Sell -- (Class A Common Stock)	124403	4.41	611135
Nov 18, 2025	F -- (Class A Common Stock)	17584	4.14	735538
Nov 6, 2025	Acquisition -- (Class A Common Stock)	84925	0	753122
Aug 19, 2025	Sell -- (Class A Common Stock)	36599	5.52	668197
Aug 16, 2025	F -- (Class A Common Stock)	3789	5.64	704796
May 16, 2025	F -- (Class A Common Stock)	3796	4.25	708585
Feb 4, 2025	Acquisition -- (Class A Common Stock)	210113	0	707085
Feb 4, 2025	F -- (Class A Common Stock)	2753	7.25	712381
Feb 4, 2025	Acquisition -- (Class A Common Stock)	8049	0	715134
Aug 2, 2024	Acquisition -- (Class A Common Stock)	496972	0	496972